Minkin et al., 2014 - Google Patents

Smoking and secondhand smoke among patients with systemic lupus erythematosus and controls: associations with disease and disease damage

Minkin et al., 2014

View PDF
Document ID
7312458038098193563
Author
Minkin S
Slan S
Gilkeson G
Kamen D
Publication year
Publication venue
Arthritis Research & Therapy

External Links

Snippet

Background Previous reports suggest smoking may be a risk factor for developing systemic lupus erythematosus (SLE). This study explores the impact of tobacco smoke on SLE patients compared with controls and on disease characteristics among patients. Methods …
Continue reading at link.springer.com (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
    • G06Q50/10—Services
    • G06Q50/22—Health care, e.g. hospitals; Social work
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Similar Documents

Publication Publication Date Title
Mukherjee et al. Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena
Kirou et al. Activation of the interferon‐α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease
Pierson et al. Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease
Lin et al. Adverse pregnancy outcomes and subsequent risk of cardiovascular disease in women with systemic lupus erythematosus
Dall'Era et al. Preliminary population-based incidence and prevalence estimates of systemic lupus erythematosus: the California Lupus Surveillance Project
Grammer et al. A comprehensive approach to identify approved drugs and treatments for repositioning as therapies for systemic lupus erythematosus
Zapantis et al. Eculizumab in recalcitrant antiphospholipid antibody syndrome
Minkin et al. Smoking and secondhand smoke among patients with systemic lupus erythematosus and controls: associations with disease and disease damage
Peschken et al. High mortality in North American Natives with systemic lupus erythematosus
Kan et al. Cluster analysis of longitudinal treatment patterns in patients newly diagnosed with systemic lupus erythematosus in the United States
Chae et al. Racial discrimination and disease damage among African American women with systemic lupus erythematosus
Ghoreishi et al. A role for cutaneous gamma delta T cells in the development of systemic lupus erythematosus
Shao et al. Aggregation of MAVS antiviral protein suggests a mechanism for increased type I interferon production in SLE
Isenberg et al. Effects of atacicept on disease activity in patients with moderate to severe systemic lupus erythematosus: APRIL-SLE randomized trial
Avina-Zubieta et al. Elevated risk of chronic obstructive pulmonary disease in systemic lupus erythematosus: a population-based study
Forbess et al. Outcome measures in systemic lupus erythematosus: constructing a meaningful response index from existing clinical trial data
Feldman et al. Sociodemographics and epidemiology of serious infections requiring hospitalization among adults with systemic lupus erythematosus and lupus nephritis, 2000 to 2006
Clark et al. Vimentin is a dominant target of in situ humoral immunity in human lupus tubulointerstitial nephritis
Olsen et al. Is prevention of systemic lupus erythematosus a goal?
Choi et al. Aberrant expansion of CXCR5+ memory CD4 T cells in patients with systemic lupus erythematosus
De et al. Targeting IRF5 inhibition in human B cells: identification of new functional roles that implicate IRF5 in systemic lupus erythematosus B-cell pathology
Doerner et al. Elucidating the role of TNF-like weak inducer of apoptosis in the pathogenesis of cutaneous lupus
Aranow Optimal determination of Physician Global Assessment of lupus disease activity: a pilot study
Fritzler The opportunity and imperative for point-of-care diagnostics in systemic lupus erythematosus
Yelin et al. Are patient ratings of interactions with providers and health plans associated with technical quality of care in systemic lupus erythematosus?